P8865
L-プロリン
別名:
(S)-ピロリジン-2-カルボン酸
ログインで組織・契約価格をご覧ください。
サイズを選択してください
この商品について
実験式（ヒル表記法）:
C5H9NO2
CAS番号:
分子量:
115.13
EC Number:
205-702-2
UNSPSC Code:
12352209
NACRES:
NA.26
Beilstein/REAXYS Number:
80810
MDL number:
InChI key
ONIBWKKTOPOVIA-BYPYZUCNSA-N
InChI
1S/C5H9NO2/c7-5(8)4-2-1-3-6-4/h4,6H,1-3H2,(H,7,8)/t4-/m0/s1
SMILES string
OC(=O)[C@@H]1CCCN1
biological source
non-animal source
assay
≥98.5%
form
crystalline powder
technique(s)
cell culture | mammalian: suitable
impurities
endotoxin, heavy metals, residual solvents, tested
mp
228 °C (dec.) (lit.)
solubility
H2O: 50 mg/mL
application(s)
pharmaceutical (small molecule)
foreign activity
cytotoxicity, tested
Quality Level
類似した製品をお探しですか？ 訪問 製品比較ガイド
関連するカテゴリー
Application
L-Proline is a non-essential amino acid. Peptides bond to Proline, making it a useful building block for proteins. It can be used as a cell culture media component for the commercial biomanufacture of therapeutic recombinant proteins and monoclonal antibodies.
General description
Our SAFC® portfolio of high-quality raw materials for use in biopharmaceutical processing withstands strict quality control procedures plus the documentation and expertise to help our customers meet requirements as defined by the M-Clarity Program.
M-Clarity Program
Our comprehensive portfolio of upstream process chemicals not only provides biopharmaceutical manufacturers with high-quality raw materials for production of classical and novel therapies, but also helps them get to market faster and simplify regulatory challenges. Trust us to deliver supply chain transparency and reliable sourcing around the globe, streamlining your product qualification with best-in-class regulatory support and service.
M-Clarity Program
Our comprehensive portfolio of upstream process chemicals not only provides biopharmaceutical manufacturers with high-quality raw materials for production of classical and novel therapies, but also helps them get to market faster and simplify regulatory challenges. Trust us to deliver supply chain transparency and reliable sourcing around the globe, streamlining your product qualification with best-in-class regulatory support and service.
To request documentation for this product, please contact Customer Support and select ‘Product Documentation′. Please note that access to the documentation for this product requires a confidentiality disclosure agreement.
Legal Information
SAFC is a registered trademark of Merck KGaA, Darmstadt, Germany
保管分類
11 - Combustible Solids
wgk
WGK 1
flash_point_f
Not applicable
flash_point_c
Not applicable
ppe
Eyeshields, Gloves, type N95 (US)
Marie Couturier et al.
The Journal of biological chemistry, 288(20), 14624-14635 (2013-04-06)
The microbial deconstruction of the plant cell wall is a key biological process that is of increasing importance with the development of a sustainable biofuel industry. The glycoside hydrolase families GH5 (PaMan5A) and GH26 (PaMan26A) endo-β-1,4-mannanases from the coprophilic ascomycete
David Saadoun et al.
Annals of the rheumatic diseases, 73(5), 831-837 (2013-04-23)
The standard-of-care treatment of patients with hepatitis C virus (HCV)-mixed cryoglobulinemia (MC) vasculitis includes pegylated interferon α (PegIFN)-α plus ribavirin and/or rituximab. About 30-40% of patients are non-responders or relapsers to such combination. To analyse the safety and efficacy of
Salvatore Petta et al.
Hepatology (Baltimore, Md.), 59(5), 1692-1705 (2014-04-03)
We assessed the cost-effectiveness of sofosbuvir (SOF)-based triple therapy (TT) compared with boceprevir (BOC)- and telaprevir (TVR)-based TT in untreated genotype 1 (G1) chronic hepatitis C (CHC) patients discriminated according to IL28B genotype, severity of liver fibrosis, and G1 subtype.
Michael P Manns et al.
Gastroenterology, 147(2), 366-376 (2014-04-15)
MK-5172 is an inhibitor of the hepatitis C virus (HCV) nonstructural protein 3/4A protease; MK-5172 is taken once daily and has a higher potency and barrier to resistance than licensed protease inhibitors. We investigated the efficacy and tolerability of MK-5172
Ewa Sawosz et al.
International journal of molecular sciences, 16(10), 25214-25233 (2015-10-30)
Our previous studies revealed that graphene had anticancer properties in experiments in vitro with glioblastoma multiforme (GBM) cells and in tumors cultured in vivo. We hypothesized that the addition of arginine or proline to graphene solutions might counteract graphene agglomeration
ライフサイエンス、有機合成、材料科学、クロマトグラフィー、分析など、あらゆる分野の研究に経験のあるメンバーがおります。.
製品に関するお問い合わせはこちら（テクニカルサービス）